AI
ORMP icon

Atria Investments’s Oramed Pharmaceuticals ORMP Stock Holding History

Atria Investments’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,426
Closed -$42.2K – 1978
2024
Q4 		$42.2K Sell
17,426
-578
-3% -$1.37K ﹤0.01% 1844
2024
Q3 		$43.9K Buy
18,004
+1,393
+8% +$3.4K ﹤0.01% 1889
2024
Q2 		$42.7K Buy
+16,611
New +$39.5K ﹤0.01% 1894

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Atria Investments's ORMP Position: Q1 2025 in Review

Atria Investments sold out of Oramed Pharmaceuticals (ORMP) in Q1 2025, closing a stake of 17,426 shares — an estimated $42.2K sold.

Atria Investments first reported a position in ORMP in Q2 2024 and held it in 3 quarters. The position peaked at $43.9K in Q3 2024. 52 funds tracked by Wall St. Rank hold ORMP as of Q1 2025.

  • Atria Investments reported no remaining Oramed Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atria Investments sold 17,426 Oramed Pharmaceuticals shares in Q1 2025, an estimated $42.2K.
  • Atria Investments first reported a position in Oramed Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Atria Investments's Oramed Pharmaceuticals position peaked at $43.9K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2025.

Based on Atria Investments's 13F filing for Q1 2025, filed 6 May 2025.